Stefano Angelini

Dr. Stefano Angelini

orcid

Research Focus & Metrics

Academic Career Length

14Years (2013-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
31 January 2013 in Blood
Verified
Journal Article
Open access
PDF file
PBPaolo Di Bartolomeo
Paolo Di Bartolomeo
SSStella Santarone
Stella Santarone
GAGottardo De Angelis
Gottardo De Angelis
APAlessandra Picardi
Alessandra Picardi
LCLaura Cudillo
Laura Cudillo
WAWilliam Arcese
William Arcese
Key Points: Haploidentical, unmanipulated, G-CSF–primed bone marrow transplantation. Haploidentical hematopoietic stem cell transplantation for hematologic malignancies.

26 May 2015 in British Journal of Haematology
Verified
Journal Article
Closed access
PDF file
DVDavide Vagnoni
Davide Vagnoni
FTFosco Travaglini
Fosco Travaglini
VPValerio Pezzoni
Valerio Pezzoni
MRMiriana Ruggieri
Miriana Ruggieri
CBCatia Bigazzi
Catia Bigazzi
PGPiero Galieni
Piero Galieni

1 April 2021 in British Journal of Haematology
Verified
Journal Article
Closed access
PDF file
PGPiero Galieni
Piero Galieni
FTFosco Travaglini
Fosco Travaglini
DVDavide Vagnoni
Davide Vagnoni
MRMiriana Ruggieri
Miriana Ruggieri
PCPatrizia Caraffa
Patrizia Caraffa
VPValerio Pezzoni
Valerio Pezzoni

24 August 2022 in Bone Marrow Transplantation
Verified
Journal Article
Closed access
PDF file
SSStella Santarone
Stella Santarone
SAStefano Angelini
Stefano Angelini
ANAnnalisa Natale
Annalisa Natale
DVDoriana Vaddinelli
Doriana Vaddinelli
RSRaffaele Spadano
Raffaele Spadano
PBPaolo Di Bartolomeo
Paolo Di Bartolomeo

1 July 2021 in Minerva Urology and Nephrology
Verified
Journal Article
Closed access
MBMarco Borghesi
Marco Borghesi
LBLorenzo Bianchi
Lorenzo Bianchi
UBUmberto Barbaresi
Umberto Barbaresi
VVValerio Vagnoni
Valerio Vagnoni
BCBeniamino Corcioni
Beniamino Corcioni
RSRiccardo Schiavina
Riccardo Schiavina
Article: Diagnostic performance of MRI/TRUS fusion-guided biopsies vs. systematic prostate biopsies in biopsy-naïve, previous negative biopsy patients and men undergoing active surveillance - Minerva Urology and Nephrology 2021 June;73(3):357-66 - Minerva Medica - Journals

9 October 2017 in Bone Marrow Transplantation
Verified
Journal Article
Open access
PDF file
SSS Santarone
S Santarone
Alessia PepeAlessia Pepe
Alessia Pepe
Antonella MeloniAntonella Meloni
Antonella Meloni
ANA Natale
A Natale
Laura PistoiaLaura Pistoia
Laura Pistoia
PBP Di Bartolomeo
P Di Bartolomeo
Hematopoietic cell transplant (HCT) recipients have a substantial risk of developing secondary solid cancers (SSCs). The aim of this retrospective study was to compare the incidence of SSC in a monocentric cohort of thalassemia major (TM) patients (n=122) who received HCT versus an hematopoietic cell donor monocentric cohort (n=122) and versus a large multicenter cohort of age- and sex-matched TM patients (n=244) who received conventional therapy. With a median follow-up of 24 years, 8 transplanted patients were diagnosed with SSC at a median of 18 years after HCT and at a median age of 33 years. Three patients died of cancer progression and 5 are living after a follow-up ranging from 10 months to 16 years after SSC diagnosis. The 30-year cumulative incidence of developing SSC was 13.24%. The occurrence of solid cancers in the hematopoietic cell donor cohort was limited to only one case for a significantly lower cumulative incidence (3.23%, P=0.02) and to 3 cases in the cohort of nontransplant patients for a significantly lower cumulative incidence (1.32%, P=0.005). This study shows that the magnitude of increased risk of SST is fourfold to sixfold for patients treated with HCT as compared with hematopoietic cell donors and nontransplant patients.